Pacylex
Pacylex is an early stage company developing a new therapy for a wide variety of cancers vulnerable because of the discovering of a previously unknown driver biology (biology responsible for the transition from normal to cancer cells). The lead therapeutic drug, PCLX-001, is water soluble, 93% orally bioavailable, and is a first-in-kind, small molecule target inhibitor with high activity in vitro and in vivo. The key biomarker is lost in 19 cancer cell lines at a prevalence ranging from 5-82% and at a much higher prevalence in tumor cells taken from patients. A predictive diagnostic test that identifies cancer patients with key biomarker is also in development. Proof of concept has been obtained in 4 of 4 hematological cancer mouse xenografts including on patient-derived xenograft (PDX) in DLBCL & AML
Conference Objective
Expand exposure of Pacylex to potential investors and corporate strategic partners
Partnering Objective
Introduce Pacylex to potential strategic partners and ascertain whether the company/product fits areas of strategic interest, who the proper contacts are for engaging and what stage does the potential strategic partner look at new oncology opportunities
Delegate Contacts
Michael has over 25 years life science executive experience, as CEO Sonescence and SEA Medical, CBO Strategent, Corium, Therashock; VP development SciDose, Auspex; Senior Program Executive Nektar, Ligand. Key roles included raising capital, establishing and maintaining business partnerships, building teams, and developing new products. He raised Seed through Series C capital and established partnerships worth more than $175 Million. Michael has driven oncology product development including during the Phase III/NDA for Targretin, and business planning for drug delivery of Leuprolide, Paclitaxel and Irinotecan. He obtained Orphan Drug and Fast Track designations in US and EU. Dr. Weickert received his Ph.D. in Genetics from the University of Wisconsin and worked at the NCI/NIH